Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian biotech company Advitech and the CHUL Research Center have revealed plans to conduct a research project to assess the potential of Advitech's growth factor complex, XP-828L, for the treatment of inflammatory bowel diseases.
Subscribe to our email newsletter
The in vivo study will use a recognized animal model of chronic inflammatory diseases, the HLA-B27T transgenic rat model. The study should be completed by the end of the second quarter of 2005 and results should be made available during the third quarter.
“This project represents an important extension of our XP-828L platform, in view of the significant market opportunities involved,” mentioned Renaud Beauchesne, Advitech’s president and CEO.
“Advitech’s project is of great interest, since it will make it possible to validate new therapeutic indications for complex diseases such as Crohn’s disease,” stated Dr Patrice Poubelle, researcher at the CHUL Research Center and Advitech’s special scientific advisor.
“The available treatments are often linked to various side effects that can be severe. Advitech’s technology could be a useful therapeutic alternative in that regard, especially because of the safety profile which appears favorable, according to a recent open study,” he continued.
Based on the results of the in vivo study, a first clinical trial on patients suffering from inflammatory bowel diseases could be undertaken in 2006.
XP-828L was already the subject of a first clinical trial in 2004 for the treatment of psoriasis and a second clinical study for this indication is currently in process.